MedTrace Logo

An Adaptive Treatment Strategy for Adolescent Depression-Continuation

NCT02017535 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-03-23

Study results available
· View outcomes & findings →

Summary

Aim 1: Assess the feasibility and acceptability of the personalized continuation treatment strategy.

Aim 2: Estimate variances of primary and secondary outcomes with the continuation treatment.

Aim 3: Conduct exploratory hypothesis-generating analyses to inform further development of the personalized continuation treatment strategy to be tested in a subsequent R01 proposal.

Conditions

  • Adolescent Depression

Interventions

DRUG

Fluoxetine

Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.

BEHAVIORAL

Interpersonal Psychotherapy

Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.

Sponsors & Collaborators

Principal Investigators

  • Meredith Gunlicks-Stoessel, PhD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2018-10-01
Completion
2018-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02017535 on ClinicalTrials.gov